Floatz logo

Benadryl

Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Aggressive B-cell Lymphoma With Secondary Involvement of the CNS cohort.

Asset / SponsorPhaseRating
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
National Cancer Institute (NCI)
Phase 1CC
Ketorolac Tromethamine
National Cancer Institute (NCI)
Phase 1CC
FENTANYL
National Cancer Institute (NCI)
Phase 1CC
Venetoclax
National Cancer Institute (NCI)
Phase 1CC
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
National Cancer Institute (NCI)
Phase 1CC

View all 12 →

Same molecule, other indications

Benadryl is also rated in:

Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →